BioSpace News Archive

Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate in the Jefferies Biotech CNS/Neuro Summit.

Axena Health, Inc. (Axena Health), a medical device company focused on female pelvic health, commends leading researchers in women’s health, who presented data showing that urinary incontinence (UI) symptom relief is durable for two-years following eight-weeks of treatment with the Leva® Pelvic Health System.

Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”) wishes to clarify certain disclosure in its management information circular (the “Circular”)

Addex Therapeutics announced that it plans to change the ratio of its American Depositary Shares to its ordinary shares from the current ADS Ratio of one ADS to six ordinary shares to a new ADS Ratio of one ADS to one hundred and twenty ordinary shares.

Syndax Pharmaceuticals announced that on October 1, 2023 the Company granted inducement awards to purchase up to 121,150 shares of common stock to eight new employees under the Company’s 2023 Inducement Plan.

Immunocore announces upcoming presentation and posters at ESMO 2023 Long-term survival data for KIMMTRAK in previously untreated patients with metastatic uveal melanoma to be presented as a late-breaking abstract in a mini oral session.

Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on October 4, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 3,000 shares of its common stock to two new employees.

Cybin Inc. today announced that its abstract describing a comprehensive structure-activity relationship study of a series of novel serotonergic phenethylamines has been selected for presentation at the Neuropsychiatric Drug Development Summit taking place October 11-12 in Boston, MA.

Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio ® (abemaciclib; a CDK4/6 inhibitor), Retevmo ® (selpercatinib; a rearranged during transfection [RET] inhibitor), and imlunestrant (an investigational oral selective estrogen receptor degrader [SERD]) will be presented at the 2023 European Society for Medical Oncology (ESMO) Congress taking place October 20-24 in Madrid.

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”) will present at the 8th Annual Dawson James Conference on Thursday, October 12, 2023, at the Wyndam Grand Jupiter at Harbourside Place in Jupiter, Florida.